Fluvastatin prevents renal injury and expression of lactin-like exidized low-density lipoprotein receptor-1 in rabbits with hypercholesterolemia

Chinese Medical Journal

Volumn 118, Issue 8, 2005, Pages 621-626

  Yu, Yong Hui ^a   Wang, Yi ^a   Dong, Bo ^a   Sun, Shu Zhen ^a   Chen, Yao ^a   Meng, Xiao Hui ^a   Liu, Zhong Zhi ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Atherosclerosis; HMG CoA reductase inhibitors; Hypercholesterolemia; Kidney disease; Low density lipoprotein; Receptors

Indexed keywords

CHOLESTEROL; CREATININE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LARD; LECTIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR 1; OXIDIZED LOW DENSITY LIPOPROTEIN; PENTETATE TECHNETIUM TC 99M; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL DIET; CONTROLLED STUDY; DRUG MECHANISM; GLOMERULUS FILTRATION RATE; HYPERCHOLESTEROLEMIA; IMMUNOHISTOCHEMISTRY; INTIMA; KIDNEY BLOOD FLOW; KIDNEY INJURY; MALE; NONHUMAN; PROTEIN EXPRESSION; RABBIT; RENAL ARTERY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VASCULAR ENDOTHELIUM;

ANIMALS; CHOLESTEROL; CREATININE; FATTY ACIDS, MONOUNSATURATED; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; IMMUNOHISTOCHEMISTRY; INDOLES; KIDNEY; MALE; RABBITS; RECEPTORS, LDL; RECEPTORS, OXIDIZED LDL; RNA, MESSENGER; SCAVENGER RECEPTORS, CLASS E; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 17844385340     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Yu YH, Dong B, Wang Y. The role of LOX-1 in the process of atherosclerosis. Foreign Med Sci (Section of Cardiovascular Diseases) (Chin) 2004; 31: 280-283.
2. Chen M, Masaki T, Sawamura T. LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: implications in endothelial dysfunction and atherosclerosis. Pharmacol Ther 2002; 95: 89-100.
3. Cattaneo D, Remuzzi G. Lipid oxidative stress and the anti-inflammatory properties of statins and ACE inhibitors. J Ren Nutr 2005; 15: 71-76.
4. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004; 57: 728-734.
5. Li H, Li X, Duan L, et al. Inhibition of lovastatin on proliferation and expression of proinflammatory cytokines in cultured human glomerular mesangial cells. Chin Med J 2003; 116: 1366-1369.
6. Tan H, Pan QX, Liang CX, et al. Losartan, captopril and combined administration on the treatment of atherosclerotic renal vascular disease. Chin J Atheroscler 2003; 11: 299-303.
7. Chen H, Li D, Sawamura T, et al. Upregulation of LOX-1 expression in aorta of hypercholesterolemic rabbits: modulation by losartan. Biochem Biophys Res Commun 2000; 276: 1100-1104.
8. Shen CX, Chen HZ, Ge JB. The role of inflammatory stress in acute coronary syndrome. Chin Med J 2004; 117: 133-139.
9. Sakabe K, Fukuda N, Wakayama K, et al. Lipid-altering changes and pleiotropic effects of atorvastatin in patients with hypercholesterolemia. Am J Cardiol 2004; 94: 497-500.
10. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000; 101: 207-213.
11. Usui H, Shikata K, Matsuda M, et al. HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. Nephrol Dial Transplant 2003; 18: 265-272.
12. Chade AR, Best PJ, Rodriguez-Porcel M, et al. Endothelial receptor blockade prevents renal injury in experimental hypercholesterolemia. Kidney Int 2003; 64: 962-969.
13. Hongjiang C, Dayuan L, Tatsuya S, et al. Upregulation of LOX-1 Expression in Aorta of hypercholesterolemic rabbits: modulation by losartan. Biochem Biophys Res Commun 2000; 276: 1100-1104.
14. Chen M, Masaki T, Sawamura T. LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: implications in endothelial dysfunction and atherosclerosis. Pharmacol Ther 2002; 95: 89-100.
15. Li D, Mehta JL. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect against oxidized low-density lipoprotein-induced endothelial dysfunction. Endothelium 2003; 10: 17-21.
16. Chen J, Mehta JL, Haider N, et al. Role of caspases in Ox-LDL-induced apoptotic cascade in human coronary artery endothelial cells. Circ Res 2004; 94: 370-376.
17. Rosenson RS. Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis 2004; 173: 1-12.
18. Baigent C, Landray M, Warren M. Statin therapy in kidney disease populations: potential benefits beyond lipid lowering and the need for clinical trials. Curr Opin Nephrol Hypertens 2004; 13: 601-605.